Sara Donati

Cardiotoxicity of Epirubicin/Paclitaxel–Containing Regimens: Role of Cardiac Risk Factors

Alessandra Gennari, B. Salvadori, Sara Donati et al. · Journal of Clinical Oncology · 1999 · 114 citations

Medicine, Oncology, Pharmacology +17

Role of 2-[18F]-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) in the Early Assessment of Response to Chemotherapy in Metastatic Breast Cancer Patients

Alessandra Gennari, Sara Donati, B. Salvadori et al. · Clinical Breast Cancer · 2000 · 103 citations · Full text

Medicine, Nuclear Medicine, Oncology +16

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11

Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Treated for up to 10 Years

Valentina Guarneri, Sara Donati, Massimiliano Nicolini et al. · The Oncologist · 2005 · 87 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*

PierFranco Conte, Alessandra Gennari, Sara Donati et al. · Breast Cancer Research and Treatment · 2001 · 72 citations · Full text

Medicine, Oncology, Pharmacology +12